Pacific Biosciences Of California, Inc 8-K/A, filed Feb 7, 2025
Pacific Biosciences Of California, Inc. (PACB)
8-K/A
2025-02-07
For: 2025-01-24
View Original
Added on
April 12, 2026
About this 8-K/A
Pacific Biosciences Of California, Inc filed this 8-K/A on February 7, 2025, reporting on events of January 24, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code)
(650 ) 521-8000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
Pacific Biosciences of California, Inc. (the “Company”) is filing this amendment to its Current Report on Form 8-K filed on January 30, 2025, which reported that the Company’s Board of Directors (the “Board”) had appointed Christopher M. Smith as a new director of the Company. At the time of his appointment, Mr. Smith was not appointed to any Board committee. On February 6, 2024, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Mr. Smith to the Science and Technology Committee of the Board, effective immediately. In connection with his appointment to the Science and Technology Committee, Mr. Smith will receive additional cash compensation as set forth in the Company’s non-employee director compensation policy, as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024. Concurrent with such appointment, upon the recommendation of the Corporate Governance and Nominating Committee of the Board, the Board appointed Marshall Mohr as chairman of the Audit Committee of the Board in place of Randy Livingston, who will continue to serve as a member of the Audit Committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Pacific Biosciences of California, Inc. | ||||||||
| By: | /s/ Brett Atkins | |||||||
| Brett Atkins | ||||||||
| General Counsel | ||||||||
| Date: February 7, 2025 | ||||||||